Mental Health

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group"), a clinical-stage life science biotechnology company pioneering the...

Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp

TORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its...

Dog Study Published in PLOS ONE Shows Statistically Significant Results for Use of Jaguar Health’s Crofelemer for Preventive Treatment of Cancer Therapy-Related Diarrhea (CTD)

This study, conducted by Jaguar family company Napo Pharmaceuticals in collaboration with Puma Biotechnology, is one of three important studies...

Fighting leprosy with artificial intelligence: DAHW and Belle.ai join forces with Senegal’s Ministry of Health and Social Action to detect and combat neglected diseases

WÜRZBURG, Germany and CAMBRIDGE, Mass., Jan. 24, 2024 (GLOBE NEWSWIRE) -- DAHW German Leprosy and Tuberculosis Relief Association and BelleTorus...

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

HOUSTON, TX, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced...

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming...

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient...

Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE:PSYG), a clinical-stage life science biotechnology company pioneering...

error: Content is protected !!